The distinction between healthy and harmful heart enlargement sits at the center of the work. Cardiac hypertrophy, the thickening of heart muscle, comes in two physiologically opposite flavors. Physiological hypertrophy, triggered by exercise or pregnancy, enlarges the heart while preserving or improving its contractile function, and it is accompanied by efficient energy metabolism, robust blood vessel growth, and molecular profiles dominated by fatty acid oxidation. Pathological hypertrophy, driven by chronic hypertension, valve disease, or heart attack, produces similar gross enlargement but with stiffening walls, impaired pumping, fibrosis, metabolic inflexibility, and a march toward heart failure. Decades of research have sought the molecular switch that separates these two trajectories, and the new findings place cytosolic NADPH firmly on the protective side of that divide.

Technically, the study hinged on the ability to see and manipulate NADPH in living systems, a long-standing challenge because NADPH and its oxidized counterpart NADP+ are structurally almost identical and interconvert rapidly. Wu and colleagues combined genetic models targeting glucose-6-phosphate dehydrogenase, or G6PD, the rate-limiting enzyme of the oxidative pentose phosphate pathway and the principal cytosolic source of NADPH, with readouts of cardiac structure, function, and metabolism. When exercise-induced increases in G6PD activity were blunted, the beneficial cardiac remodeling that normally follows training was lost, demonstrating that the pathway is not merely a byproduct of exercise but a necessary component of its cardiac benefits.

The protective payoff became most apparent in models of ischemia/reperfusion injury, the cellular catastrophe that occurs when blood supply to the heart is briefly cut off and then restored, as happens during a heart attack. Animals with elevated cytosolic NADPH, whether achieved through exercise or through the spermidine-derived compound, showed improved cardiac function and reduced injury after the insult. The team traced this protection to NADPH’s established biochemical roles: the molecule is the electron donor for thioredoxin and glutathione antioxidant systems that neutralize reactive oxygen species, the corrosive byproducts of reoxygenation that kill cardiomyocytes in the minutes and hours after blood flow returns. By keeping antioxidant capacity high, elevated NADPH effectively raises the heart’s threshold for reperfusion damage.

What makes the result especially compelling is the pharmacological angle. Spermidine itself has been linked in prior studies to cardioprotection and extended healthspan, prompting interest in its derivatives as drug candidates. Wu and colleagues identified a candidate spermidine derivative that raises cytosolic NADPH and reproduces key features of the exercise phenotype: physiological growth of the heart, enhanced antioxidant buffering, and resilience to ischemic injury, without the maladaptive gene expression patterns that characterize pathological hypertrophy. In effect, the compound simulates a metabolic signature of the trained heart in sedentary animals.

The concept of an exercise-mimicking pill has long hovered at the edge of cardiovascular research, often disappointing in translation because broad interventions that mimic one aspect of exercise tend to disrupt others. The NADPH-centered approach is narrower and, its proponents argue, more principled. Rather than attempting to replicate the whole-body storm of hormones, neural signals, and mechanical loading that exercise produces, the strategy targets a single downstream metabolite that sits at a convergence point for the cardiac benefits of training. NADPH is consumed in the synthesis of reduced glutathione, regenerated by G6PD and by malic enzyme and isocitrate dehydrogenase reactions, and shuttled across compartments by dedicated transporters, making its cytosolic pool a well-positioned control point for redox homeostasis.

The study also builds on a growing appreciation that NADPH metabolism is not uniform across cellular compartments. Mitochondrial NADPH, generated by transhydrogenase and other enzymes, has distinct roles in antioxidant defense and biosynthesis, while nuclear and cytosolic pools feed separate redox circuits. By focusing specifically on the cytosolic compartment and linking it to G6PD flux, the work offers a more precise target than earlier, cruder attempts to boost cellular reduction potential. Fluorescent biosensors that distinguish NADPH from NADH, developed in recent years, made the compartment-specific measurements feasible and are likely to accelerate follow-up studies in other tissues where NADPH balance governs immune function, fat metabolism, and aging.

Important caveats remain before the findings can inform human medicine. The work was conducted in animal models, and the dose, safety, and long-term consequences of chronically elevating cytosolic NADPH are unknown. Excessive NADPH generation has been implicated in other contexts in fueling proliferative signaling and in providing reducing equivalents to NADPH oxidases, which produce the very reactive oxygen species the heart must defend against. The authors and commentators, including Bryce J. Carpenter and Pieterjan Dierickx of the Max Planck Institute for Heart and Lung Research, who wrote an accompanying News and Views analysis, emphasize that the therapeutic window will need careful definition: the goal is the physiological range achieved by exercise, not an unbounded increase. Questions also remain about whether NADPH elevation alone can recapitulate the vascular and neuronal adaptations of exercise or whether it must be paired with other signals.

Even with those qualifications, the study reframes a central question in cardiovascular medicine. If the protective effects of exercise on the heart converge on a measurable metabolite, then patients confined to hospital beds, older adults with frailty, and the vast population that fails to meet physical activity guidelines may one day have access to a therapy that borrows the heart’s own training program. A candidate spermidine derivative that lifts cytosolic NADPH is an early but concrete step along that path, and it signals that the metabolic underpinnings of exercise’s benefits are finally becoming druggable.

Subject of Research: The role of cytosolic NADPH produced by the pentose phosphate pathway in mediating exercise-induced physiological cardiac hypertrophy and protection against ischemia/reperfusion injury.

Article Title: Increasing cytosolic NADPH to mimic exercise

Article References: Increasing cytosolic NADPH to mimic exercise. (n.d.). https://doi.org/10.1038/s42255-026-01580-2

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01580-2

Keywords: NADPH, cardiac hypertrophy, exercise mimicry, pentose phosphate pathway, G6PD, spermidine, ischemia/reperfusion injury, heart failure, cardiac metabolism, antioxidant defense, Nature Metabolism, cardioprotection